Thromboprophylaxis for Hip and Knee Arthroplasty: Current Managements and Review of the Literature

Ismail Hakki Korucu^1*, Faik Turkmen¹, Burkay Kacira¹, Onur Bilge¹, Alper Kilicaslan², Serdar Toker¹

¹Orthopaedic and Traumatology Department, Meram School of Medicine, Necmettin Erbakan University, Konya, Turkey.
²Anesthesiology Department, Meram School of Medicine, Necmettin Erbakan University, Konya, Turkey.

DOI: 10.4236/wjcd.2014.412071                

Abstract

Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) are major surgical procedures which can cause high morbidity and even mortality. Among these complications is venous thrombo embolism (VTE) comprising deep vien thrombosis (DVT) and pulmonary embolism (PE). Therefore, after these operations, thromboprophylaxis is routinely used. However, it has some complications such as bleeding, adverse effect of chemical agents for using prevention of DVT. Anti-thrombotic prophylaxis includes: low molecular weight heparin (LMWH), fondaparinux, apixaban, dabigatran, rivaroxaban, low dose unfractionated heparin (LDUH), adjusted dose vitamin K antagonist (VKA), aspirin, or mechanical thromboprophylaxis devices. All over the World, orthopaedic surgeons consider a balance between thromboprophylaxis and bleeding. However, it has been still controversy about optimum prophylaxis for DVT. In this current paper, we aimed to review the literature under light of the current studies.

Keywords

Total Hip Arthroplasty, Total Knee Arthroplasty, Thromboprophylaxis

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	FalckYtter, Y., Francis, C.W., Johanson, N.A., et al. (2012) Prevention of VTE in Orthopedic Surgery Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141, e279S-e325S.
[2]	Geerts, W.H., Bergqvist, D., Pineo, G.F., et al. (2008) Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th edn. Chest, 133, 381S-453S.
[3]	Burnett, R.S., Clohisy, J.C., Wright, R.W., McDonald, D.J., Shively, R.A., Givens, S.A. and Barrack, R.L. (2007) Failure of the American College of Chest Physicians-1A Protocol for Lovenox in Clinical Outcomes for Thromboembolic Prophylaxis. The Journal of Arthroplasty, 22, 317-324. http://dx.doi.org/10.1016/j.arth.2007.01.007
[4]	Walsh, M., Preston, C., Bong, M., Patel, V. and Di Cesare, P.E. (2007) Relative Risk Factors for Requirement of Blood Transfusion after Total Hip Arthroplasty. The Journal of Arthroplasty, 22, 1162-1167. http://dx.doi.org/10.1016/j.arth.2006.10.014
[5]	Schulman, S., Angeras, U., Bergqvist, D., Eriksson, B., Lassen, M.R. and Fisher, W. (2010) Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of Major Bleeding in Clinical Investigations of Antihemostatic Medicinal Products in Surgical Patients. Journal of Thrombosis and Haemostasis, 8, 202-204. http://dx.doi.org/10.1111/j.1538-7836.2009.03678.x
[6]	Geerts, W.H., Pineo, G.F., Heit, J.A., et al. (2004) Prevention of Venous Thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 126, 338S-400S. http://dx.doi.org/10.1378/chest.126.3_suppl.338S
[7]	Jacobs, J.J., Mont, M.A., Bozic, K.J., Della Valle, C.J., Goodman, S.B., Lewis, C.G., et al. (2012) American Academy of Orthopaedic Surgeons Clinical Practice Guideline on: Preventing Venous Thromboembolic Disease in Patients Undergoing Elective Hip and Knee Arthroplasty. Journal of Bone and Joint Surgery, 94, 746-747. http://dx.doi.org/10.2106/JBJS.9408.ebo746
[8]	American Academy of Orthopaedic Surgeons (AAOS) (2007) American Academy of Orthopaedic Surgeons Clinical Guideline on Prevention of Symptomatic Pulmonary Embolism in Patients Undergoing Total Hip or Knee Arthroplasty. AAOS, Rosemont. www.aaos.org/Research/guidelines/PE_guideline.pdf
[9]	American Academy of Orthopedic Surgeons (2011) Preventing Venous Thromboembolic Disease in Patients Undergoing Elective Hip and Knee Arthroplasty: Evidence-Based Guidelines and Evidence Report. www.aaos.org/research/guidelines/VTE/VTE_full_guideline.pdf
[10]	Merli, G.J. and Groce, J.B. (2010) Pharmacological and Clinical Differences between Low-Molecular-Weight-Heparins. Implications for Prescribing Practice and Therapeutic Interchange. Physical Therapy, 35, 95-105.
[11]	Leclerc, J.R., Geerts, W.H., Desjardins, L., et al. (1996) Prevention of Venous Thromboembolism after Knee Arthroplasty. A Randomized, Doubleblind Trial Comparing Enoxaparin with Warfarin. Annals of Internal Medicine, 124, 619-626. http://dx.doi.org/10.7326/0003-4819-124-7-199604010-00001
[12]	Fitzgerald Jr., R.H., Spiro, T.E., Trowbridge, A.A., et al. (2001) Prevention of Venous Thromboembolic Disease Following Primary Total Knee Arthroplasty. A Randomized, Multicenter, Open-Label, Parallel-Group Comparison of Enoxaparin and Warfarin. The Journal of Bone and Joint Surgery. American Volume, 83-A, 900-906.
[13]	Westrich, G.H., Haas, S.B., Mosca, P. and Peterson, M. (2000) Meta-Analysis of Thromboembolic Prophylaxis after Total Knee Arthroplasty. The Journal of Bone and Joint Surgery. British Volume, 82, 795-800. http://dx.doi.org/10.1302/0301-620X.82B6.9869
[14]	Brookenthal, K.R., Freedman, K.B., Lotke, P.A., et al. (2001) A Meta-Analysis of Thromboembolic Prophylaxis in Total Knee Arthroplasty. The Journal of Arthroplasty, 16, 293-300. http://dx.doi.org/10.1054/arth.2001.21499
[15]	Outes, G.A., Fernandez, A.I.T., Gea, L.S. and Castrillon, E.V. (2012) Dabigatran, Rivaroxaban, or Apixaban vs Enoxaparin for Thromboprophylaxis after Total Hip or Knee Replacement: Systematic Review, Meta-Analysis, and Indirect Treatment Comparison. BMJ, 344, e3675. http://dx.doi.org/10.1136/bmj.e3675
[16]	Kirley, K., Qato, D.M., Kornfield, R., Stafford, R.S. and Alexander, G.C. (2012) National Trends in Oral Anticoagulants Use in the United States, 2007-2011. Circulation: Cardiovascular Quality and Outcomes, 5, 615-621. http://dx.doi.org/10.1161/CIRCOUTCOMES.112.967299
[17]	Hull, R., Raskob, G., Pineo, G., et al. (1993) A Comparison of Subcutaneous Low-Molecular-Weight Heparin with Warfarin Sodium for Prophylaxis against Deep-Vein Thrombosis after Hip or Knee Implantation. The New England Journal of Medicine, 329, 1370-1376. http://dx.doi.org/10.1056/NEJM199311043291902
[18]	Geerts, W.H., Heit, J.A., Clagett, G.P., et al. (2001) Prevention of Venous Thromboembolism. Chest, 119, 132S-175S. http://dx.doi.org/10.1378/chest.119.1_suppl.132S
[19]	Lotke, P.A. and Lonner, J.H. (2006) The Benefit of Aspirin Chemoprophylaxis for Thromboembolism after Total Knee Arthroplasty. Clinical Orthopaedics and Related Research, 452, 175-180. http://dx.doi.org/10.1097/01.blo.0000238822.78895.95
[20]	Fuji, T., Fujita, S. and Ochi, T. (2008) Fondaparinux Prevents Venous Thromboembolism after Joint Replacement Surgery in Japanese Patients. International Orthopaedics, 32, 443-451. http://dx.doi.org/10.1007/s00264-007-0360-7
[21]	Ralay-Ranaivo, B., Desmaele, D., Bianchini, E.P., Lepeltier, E., Bourgaux, C., Borgel, D., Pouget, T., Tranchant, J.F., Couvreur, P. and Gref, R. (2014) Novel Self Assembling Nanoparticles for the Oral Administration of Fondaparinux: Synthesis, Characterization and in Vivo Evaluation. Journal of Controlled Release, 194C, 323-331
[22]	Bauer, K.A., Eriksson, B.I., Lassen, M.R. and Turpie, A.G. (2001) Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Elective Major Knee Surgery. The New England Journal of Medicine, 345, 1305-1310. http://dx.doi.org/10.1056/NEJMoa011099
[23]	Turpie, A.G., Bauer, K.A., Eriksson, B.I. and Lassen, M.R., PENTATHALON 2000 Study Steering Committee (2002) Postoperative Fondaparinux vs Postoperative Enoxaparin for Prevention of Venous Thromboembolism after Elective Hip-Replacement Surgery: A Randomized Double-Blind Trial. The Lancet, 359, 1721-1726. http://dx.doi.org/10.1016/S0140-6736(02)08648-8
[24]	Eriksson, B.I., Quinlan, D.J. and Weitz, J.I. (2009) Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development. Clinical Pharmacokinetics, 48, 1-22. http://dx.doi.org/10.2165/0003088-200948010-00001
[25]	Kubitza, D., Becka, M., Voith, B., et al. (2005) Safety, Pharmacodynamics, and Pharmacokinetics of Single Doses of BAY 59-7939 an Oral, Direct Factor Xa Inhibitor. Clinical Pharmacology Therapeutics, 78, 412-421. http://dx.doi.org/10.1016/j.clpt.2005.06.011
[26]	Xarelto (Rivaroxaban) Summary of Product Characteristics. Bayer Schering Pharma. Accessed 26 February 2012. http://www.xarelto.com/html/downloads/Xarelto-prescribing_information-Nov-(2012).pdf
[27]	Eriksson, B.I., Borris, L.C., Friedman, R.J., et al. (2008) Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty. The New England Journal of Medicine, 358, 2765-2775. http://dx.doi.org/10.1056/NEJMoa0800374
[28]	Kakkar, A.K., Brenner, B., Dahl, O.E., et al. (2008) Extended Duration Rivaroxaban versus Short-Term Enoxaparin for the Prevention of Venous Thromboembolism after Total Hip Arthroplasty: A Double-Blind, Randomised Controlled Trial. The Lancet, 372, 31-39. http://dx.doi.org/10.1016/S0140-6736(08)60880-6
[29]	Lassen, M.R., Ageno, W., Borris, L.C., et al. (2008) Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty. The New England Journal of Medicine, 358, 2776-2786. http://dx.doi.org/10.1056/NEJMoa076016
[30]	Turpie, A.G., Lassen, M.R., Davidson, B.L., et al. (2009) Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty (RECORD4): A Randomised Trial. The Lancet, 373, 1673-1680. http://dx.doi.org/10.1016/S0140-6736(09)60734-0
[31]	Raghavan, N., Frost, C.E., Yu, Z., et al. (2009) Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans. Drug Metabolism and Disposition, 37, 74-81. http://dx.doi.org/10.1124/dmd.108.023143
[32]	Pfizer, Inc. Eliquis (Apixaban) (2011) Summary of Product Characteristics. Middlesex, UK. Accessed 1 October 2012. www.ema.europaeu/docs/en_GB/document_library/EPAR_Product_Information/human/002148/WC500107728.pdf
[33]	Bristol-Myers Squibb and Pfizer EEIG (2012) Eliquis® (apixaban tablets) Summary of Product Characteristics. accessed 10 April 2013.
[34]	Boehringer Ingelheim Pharmaceuticals (2011) Pradaxa (dabigatran) Summary of Product Characteristics. Ridgefield, CT.
[35]	Stangier, J., Rathgen, K., Staehle, H., et al. (2007) The Pharmacokinetics, Pharmacodynamics and Tolerability of Dabigatran Etexilate, a New Oral Direct Thrombin Inhibitor, in Healthy Male Subjects. British Journal of Clinical Pharmacology, 64, 292-303. http://dx.doi.org/10.1111/j.1365-2125.2007.02899.x
[36]	Di Nisio, M., Middeldorp, S. and Buller, H.R. (2005) Direct Thrombin Inhibitors. The New England Journal of Medicine, 353, 1028-1040. http://dx.doi.org/10.1056/NEJMra044440
[37]	Eriksson, B.I., Dahl, O.E., Rosencher, N., et al. (2007) Dabigatran Etexilate versus Enoxaparin for Prevention of Venous Thromboembolism after Total Hip Replacement: A Randomized, Double-Blind, Noninferiority Trial. The Lancet, 370, 949-956. http://dx.doi.org/10.1016/S0140-6736(07)61445-7
[38]	Ginsberg, J.S., Davidson, B.L., et al., RE-MOBILIZE Writing Committee (2009) The Oral Thrombin Inhibitor Dabigatran Etexilate vs the North American Enoxaparin Regimen for the Prevention of Venous Thromboembolism after Knee Arthroplasty Surgery. The Journal of Arthroplasty, 2, 1-9.
[39]	Eriksson, B.I., Dahl, O.E., Rosencher, N., et al. (2007) Oral Dabigatran Etexilate versus Subcutaneous Enoxaparin for the Prevention of Venous Thromboembolism after Total Knee Replacement: The RE-MODEL Randomized Trial. Journal of Thrombosis and Haemostasis, 5, 2178-2185. http://dx.doi.org/10.1111/j.1538-7836.2007.02748.x
[40]	Hak, D.J. (2001) Prevention of Venous Thromboembolism in Trauma and Long Bone Fractures. Current Opinion in Pulmonary Medicine, 7, 338-343. http://dx.doi.org/10.1097/00063198-200109000-00015
[41]	Morris, R.J. and Woodcock, J.P. (2010) Intermittent Pneumatic Compression or Graduated Compression Stockings for Deep Vein Thrombosis Prophylaxis? A Systematic Review of Direct Clinical Comparisons. Annals of Surgery, 251, 393-396. http://dx.doi.org/10.1097/SLA.0b013e3181b5d61c
[42]	Sachdeva, A., Dalton, M., Amaragiri, S.V. and Lees, T. (2010) Elastic Compression Stockings for Prevention of Deep Vein Thrombosis. Cochrane Database of Systematic Reviews, 7, Article ID: CD001484. http://dx.doi.org/10.1002/14651858.CD001484.pub2
[43]	Lapidus, L.J., Ponzer, S., Pettersson, H. and de Bri, E. (2013) Symptomatic Venous Thromboembolism and Mortality in Orthopaedic Surgery—An Observational Study of 45,968 Consecutive Procedures. BMC Musculoskeletal Disorders, 14, 177. http://dx.doi.org/10.1186/1471-2474-14-177
[44]	Colwell Jr., C.W., Froimson, M.I., Mont, M.A., et al. (2010) Thrombosis Prevention after Total Hip Arthroplasty: A Prospective, Randomized Trial Comparing a Mobile Compression Device with Low-Molecular-Weight Heparin. Journal of Bone and Joint Surgery. American Volume, 92-A, 527-535.